Travere Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 54.17 million compared to USD 54.62 million a year ago. Net loss was USD 67.03 million compared to USD 39.01 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 0.64 a year ago.
For the six months, revenue was USD 102.65 million compared to USD 102.02 million a year ago. Net loss was USD 143 million compared to USD 92.88 million a year ago. Basic loss per share from continuing operations was USD 2.26 compared to USD 1.59 a year ago.